Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the June 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the December 2027 expiration. One of the key inputs that goes into the price an option buyer is ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the June 2024 expiration. One of the key data points that goes into the price an option buyer is ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the August 2025 expiration. One of the key inputs that goes into the price an option buyer is willing ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the July 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Fintel reports that on May 14, 2024, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Perform to Outperform. Analyst Price Forecast Suggests 29.21% Upside As of May ...

Here are some of the largest recent moves: CAPITAL INTERNATIONAL INVESTORS added 2,437,855 shares (+38.9%) to their portfolio in Q4 2024, for an estimated $296,418,789 UBS GROUP AG added 1,115,826 ...

Today, using the Stock Screener tool, we’ve selected two stocks with a "Perfect 10" score and a Strong Buy consensus rating: XPO Logistics (NYSE:XPO) and Sarepta Therapeutics (NASDAQ:SRPT).But ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 5.3% resulting in a US$375m addition to the ...

The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases ...